DOCSLIB.ORG

Illinois Medicaid Preferred Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Illinois Medicaid Preferred Drug List Illinois Medicaid Preferred Drug List Effective January 1, 2020 (Updated January 27, 2020) ▪ The Preferred Drug List (PDL) has products listed in groups by drug class, drug name, dosage form, and PDL status ▪ Multi-source drugs are listed by both brand and generic names when applicable ▪ ADHD Agents: Prior authorization required for participants under 6 years of age and participants 19 years of age and older ▪ Spiriva AER 1.25mcg: Prior authorization NOT required for participants ages 6-17 years ▪ Budesonide: Prior authorization NOT required for participants age 7 years and under ▪ Anticonvulsants: Prior authorization NOT required for non-preferred epilepsy agents for those participants with a diagnosis of epilepsy or seizure disorder in Department records ▪ Antipsychotics: Prior authorization required for participants under 8 years of age and long-term care residents ▪ For drugs not found on this list, go to the drug search engine at: www.ilpriorauth.com Page 1 of 92 DOSAGE DRUG CLASS DRUG NAME PDL STATS FORM ADHD / ANTI-NARCOLEPSY AGENTS : AMPHETAMINES ADZENYS ER SUER NON_PREFERRED AMPHETAMINE ER SUER NON_PREFERRED DYANAVEL XR SUER NON_PREFERRED ADZENYS XR-ODT TBED NON_PREFERRED AMPHETAMINE SULFATE TABS NON_PREFERRED EVEKEO TABS NON_PREFERRED EVEKEO ODT TBDP NON_PREFERRED DEXEDRINE CP24 NON_PREFERRED DEXTROAMPHETAMINE SULFATE ER CP24 NON_PREFERRED DEXTROAMPHETAMINE SULFATE SOLN NON_PREFERRED PROCENTRA SOLN NON_PREFERRED DEXTROAMPHETAMINE SULFATE TABS NON_PREFERRED ZENZEDI TABS NON_PREFERRED VYVANSE CAPS PREFERRED VYVANSE CHEW PREFERRED DESOXYN TABS NON_PREFERRED METHAMPHETAMINE HCL TABS NON_PREFERRED ADDERALL XR CP24 NON_PREFERRED AMPHETAMINE/DEXTROAMPHETAMINE CP24 PREFERRED MYDAYIS CP24 NON_PREFERRED ADDERALL TABS NON_PREFERRED AMPHETAMINE/DEXTROAMPHETAMINE TABS PREFERRED ADHD / ANTI-NARCOLEPSY AGENTS : MISC CLONIDINE HCL ER TB12 PREFERRED CLONIDINE HYDROCHLORIDE TB12 PREFERRED CLONIDINE HYDROCHLORIDE ER TB12 PREFERRED GUANFACINE ER TB24 PREFERRED GUANFACINE HYDROCHLORIDE TB24 PREFERRED INTUNIV TB24 NON_PREFERRED ATOMOXETINE CAPS NON_PREFERRED ATOMOXETINE HYDROCHLORIDE CAPS NON_PREFERRED STRATTERA CAPS NON_PREFERRED SUNOSI TABS NON_PREFERRED ADHD / ANTI-NARCOLEPSY AGENTS : STIMULANTS ARMODAFINIL TABS NON_PREFERRED NUVIGIL TABS NON_PREFERRED DEXMETHYLPHENIDATE HCL ER CP24 NON_PREFERRED DEXMETHYLPHENIDATE HYDROCHLORIDE CP24 NON_PREFERRED DEXMETHYLPHENIDATE HYDROCHLORIDE ER CP24 NON_PREFERRED FOCALIN XR CP24 PREFERRED DEXMETHYLPHENIDATE HCL TABS PREFERRED DEXMETHYLPHENIDATE HYDROCHLORIDE TABS PREFERRED FOCALIN TABS NON_PREFERRED DAYTRANA PTCH NON_PREFERRED COTEMPLA XR-ODT TBED NON_PREFERRED QUILLICHEW ER CHER NON_PREFERRED METHYLPHENIDATE HYDROCHLORIDE CHEW NON_PREFERRED ADHANSIA XR CP24 NON_PREFERRED APTENSIO XR CP24 NON_PREFERRED Page 2 of 92 DOSAGE DRUG CLASS DRUG NAME PDL STATS FORM JORNAY PM CP24 NON_PREFERRED METHYLPHENIDATE HYDROCHLORIDE ER CP24 NON_PREFERRED METHYLPHENIDATE HYDROCHLORIDE ER (LA) CP24 NON_PREFERRED RITALIN LA CP24 NON_PREFERRED METHYLPHENIDATE HYDROCHLORIDE CD CPCR NON_PREFERRED METHYLPHENIDATE HYDROCHLORIDE ER CPCR NON_PREFERRED METHYLIN SOLN NON_PREFERRED METHYLPHENIDATE HYDROCHLORIDE SOLN NON_PREFERRED QUILLIVANT XR SUSR NON_PREFERRED METHYLPHENIDATE HYDROCHLORIDE TABS PREFERRED RITALIN TABS NON_PREFERRED METHYLPHENIDATE HYDROCHLORIDE ER TB24 NON_PREFERRED METHYLPHENID TAB 10MG ER TBCR PREFERRED METHYLPHENID TAB 20MG ER TBCR PREFERRED CONCERTA TBCR PREFERRED METHYLPHENID TAB 18MG ER TBCR NON_PREFERRED METHYLPHENID TAB 27MG ER TBCR NON_PREFERRED METHYLPHENID TAB 36MG ER TBCR NON_PREFERRED METHYLPHENID TAB 54MG ER TBCR NON_PREFERRED METHYLPHENID TAB 72MG ER TBCR NON_PREFERRED METHYLPHENIDATE HYDROCHLO TBCR NON_PREFERRED RELEXXII TBCR NON_PREFERRED MODAFINIL TABS NON_PREFERRED PROVIGIL TABS NON_PREFERRED ANALGESICS - ANTI-INFLAMMATORY : MISC RIDAURA CAPS NON_PREFERRED OTREXUP SOAJ NON_PREFERRED RASUVO SOAJ NON_PREFERRED ARAVA TABS NON_PREFERRED LEFLUNOMIDE TABS PREFERRED ANALGESICS - ANTI-INFLAMMATORY : NONSTEROIDAL ANTI- INFLAMMATORY AGENTS (NSAIDs) ZORVOLEX CAPS NON_PREFERRED ZIPSOR CAPS NON_PREFERRED DICLOFENAC POTASSIUM TABS PREFERRED DICLOFENAC SODIUM ER TB24 PREFERRED DICLOFENAC SODIUM DR TBEC PREFERRED ETODOLAC CAPS PREFERRED ETODOLAC TABS PREFERRED ETODOLAC ER TB24 PREFERRED FENOPROFEN CALCIUM CAPS NON_PREFERRED NALFON CAPS NON_PREFERRED FENOPROFEN CALCIUM TABS NON_PREFERRED NALFON TABS NON_PREFERRED FLURBIPROFEN TABS PREFERRED IBUPROFEN SUSP NON_PREFERRED IBU TABS PREFERRED IBUPROFEN TABS PREFERRED INDOMETHACIN CAPS PREFERRED Page 3 of 92 DOSAGE DRUG CLASS DRUG NAME PDL STATS FORM TIVORBEX CAPS NON_PREFERRED INDOMETHACIN ER CPCR PREFERRED INDOCIN SUPP NON_PREFERRED INDOCIN SUSP NON_PREFERRED KETOPROFEN ER CP24 NON_PREFERRED SPRIX SOLN NON_PREFERRED KETOROLAC TROMETHAMINE TABS PREFERRED MECLOFENAMATE SODIUM CAPS NON_PREFERRED MEFENAMIC ACID CAPS NON_PREFERRED VIVLODEX CAPS NON_PREFERRED MELOXICAM TABS PREFERRED MOBIC TABS NON_PREFERRED QMIIZ ODT TBDP NON_PREFERRED NABUMETONE TABS PREFERRED RELAFEN DS TABS NON_PREFERRED NAPROXEN SUSP PREFERRED NAPROXEN TABS PREFERRED EC-NAPROXEN TBEC NON_PREFERRED NAPROXEN DR TBEC PREFERRED NAPROXEN SODIUM TABS PREFERRED NAPRELAN TB24 NON_PREFERRED NAPROXEN SODIUM TB24 NON_PREFERRED NAPROXEN SODIUM CR TB24 NON_PREFERRED NAPROXEN SODIUM ER TB24 NON_PREFERRED DAYPRO TABS NON_PREFERRED OXAPROZIN TABS NON_PREFERRED FELDENE CAPS NON_PREFERRED PIROXICAM CAPS NON_PREFERRED SULINDAC TABS PREFERRED TOLMETIN SODIUM CAPS NON_PREFERRED TOLMETIN SODIUM TABS NON_PREFERRED CELEBREX CAPS NON_PREFERRED CELECOXIB CAPS PREFERRED INFLAMMACIN THPK NON_PREFERRED ARTHROTEC 50 TBEC NON_PREFERRED ARTHROTEC 75 TBEC NON_PREFERRED DICLOFENAC SODIUM/MISOPROSTOL TBEC NON_PREFERRED DUEXIS TABS NON_PREFERRED VIMOVO TBEC NON_PREFERRED ANALGESICS - NONNARCOTIC DIFLUNISAL TABS PREFERRED SALSALATE TABS PREFERRED BUTALBITAL/ACETAMINOPHEN CAPS NON_PREFERRED ALLZITAL TABS NON_PREFERRED BUPAP TABS NON_PREFERRED BUTALBITAL/ACETAMINOPHEN TABS PREFERRED BUTALBITAL/ACETAMINOPHEN/ CAPS PREFERRED BUTALBITAL/ACETAMINOPHEN/CAFFEINE CAPS PREFERRED Page 4 of 92 DOSAGE DRUG CLASS DRUG NAME PDL STATS FORM ESGIC CAPS PREFERRED FIORICET CAPS NON_PREFERRED ZEBUTAL CAPS PREFERRED VANATOL LQ SOLN NON_PREFERRED VANATOL S SOLN NON_PREFERRED BUTALBITAL/ACETAMINOPHEN/CAFFEINE TABS PREFERRED ESGIC TABS NON_PREFERRED BUTALBITAL/ASPIRIN/CAFFEINE CAPS PREFERRED FIORINAL CAPS NON_PREFERRED BUTALBITAL/ASPIRIN/CAFFEINE TABS PREFERRED ANALGESICS : OPIOID CODEINE SULFATE TABS PREFERRED DURAGESIC PT72 NON_PREFERRED FENTANYL PT72 NON_PREFERRED ACTIQ LPOP NON_PREFERRED FENTANYL CITRATE ORAL TRANSMUCOSAL LPOP NON_PREFERRED LAZANDA SOLN NON_PREFERRED ABSTRAL SUBL NON_PREFERRED FENTANYL CITRATE TABS NON_PREFERRED FENTORA TABS NON_PREFERRED HYDROCODONE BITARTRATE ER C12A NON_PREFERRED ZOHYDRO ER C12A NON_PREFERRED HYSINGLA ER T24A NON_PREFERRED DILAUDID LIQD NON_PREFERRED HYDROMORPHONE HCL LIQD PREFERRED HYDROMORPHONE HCL SUPP PREFERRED HYDROMORPHONE HCL ER T24A NON_PREFERRED HYDROMORPHONE HYDROCHLORIDE ER T24A NON_PREFERRED DILAUDID TABS NON_PREFERRED HYDROMORPHONE HCL TABS PREFERRED LEVORPHANOL TARTRATE TABS NON_PREFERRED MEPERIDINE HCL SOLN NON_PREFERRED MEPERIDINE HCL TABS NON_PREFERRED METHADONE HCL CONC NON_PREFERRED METHADONE HCL INTENSOL CONC NON_PREFERRED METHADOSE CONC NON_PREFERRED METHADOSE SUGAR-FREE CONC NON_PREFERRED METHADONE HCL SOLN NON_PREFERRED DOLOPHINE TABS NON_PREFERRED METHADONE HCL TABS NON_PREFERRED METHADONE HYDROCHLORIDE TABS NON_PREFERRED METHADONE HCL TBSO NON_PREFERRED METHADOSE TBSO NON_PREFERRED KADIAN CP24 NON_PREFERRED MORPHINE SULFATE ER CP24 NON_PREFERRED MORPHINE SULFATE SOLN PREFERRED MORPHINE SULFATE SUPP PREFERRED MORPHABOND ER T12A NON_PREFERRED Page 5 of 92 DOSAGE DRUG CLASS DRUG NAME PDL STATS FORM MORPHINE SULFATE TABS PREFERRED MORPHINE SULFATE ER TBCR PREFERRED_WITH_PA MS CONTIN TBCR NON_PREFERRED ARYMO ER TBEA NON_PREFERRED MORPHINE SULFATE ER CP24 NON_PREFERRED XTAMPZA ER C12A NON_PREFERRED OXYCODONE HCL CAPS PREFERRED OXYCODONE HYDROCHLORIDE CAPS PREFERRED OXYCODONE HCL CONC PREFERRED OXYCODONE HYDROCHLORIDE CONC PREFERRED OXYCODONE HYDROCHLORIDE SOLN PREFERRED OXYCODONE HCL ER T12A NON_PREFERRED OXYCODONE HYDROCHLORIDE ER T12A NON_PREFERRED OXYCONTIN T12A NON_PREFERRED OXAYDO TABA NON_PREFERRED OXYCODONE HCL TABS PREFERRED OXYCODONE HYDROCHLORIDE TABS PREFERRED ROXICODONE TABS NON_PREFERRED OPANA TABS NON_PREFERRED OXYMORPHONE HYDROCHLORIDE TABS NON_PREFERRED OXYMORPHONE HYDROCHLORIDE ER TB12 NON_PREFERRED OXYMORPHONE HYDROCHLORIDEER TB12 NON_PREFERRED NUCYNTA TABS NON_PREFERRED NUCYNTA ER TB12 NON_PREFERRED CONZIP CP24 NON_PREFERRED TRAMADOL HCL ER CP24 NON_PREFERRED TRAMADOL HCL TABS PREFERRED ULTRAM TABS NON_PREFERRED TRAMADOL HCL ER TB24 NON_PREFERRED BUPRENORPHINE PTWK NON_PREFERRED BUTRANS PTWK NON_PREFERRED BELBUCA FILM NON_PREFERRED BUTORPHANOL TARTRATE SOLN NON_PREFERRED PENTAZOCINE/NALOXONE HCL TABS NON_PREFERRED ANALGESICS : OPIOID COMBINATIONS APADAZ TABS NON_PREFERRED BENZHYDROCODONE/ACETAMINOPHEN TABS NON_PREFERRED ENDOCET TABS PREFERRED NALOCET TABS NON_PREFERRED OXYCODONE/ACETAMINOPHEN TABS PREFERRED PERCOCET TABS NON_PREFERRED PRIMLEV TABS NON_PREFERRED OXYCODONE/ASPIRIN TABS NON_PREFERRED OXYCODONE/IBUPROFEN TABS NON_PREFERRED ACETAMINOPHEN/CODEINE SOLN PREFERRED ACETAMINOPHEN/CODEINE TABS PREFERRED ACETAMINOPHEN/CODEINE PHOSPHATE TABS PREFERRED TYLENOL/CODEINE #3 TABS NON_PREFERRED Page 6 of 92 DOSAGE DRUG CLASS DRUG NAME PDL STATS FORM TYLENOL/CODEINE #4 TABS NON_PREFERRED BUTALBITAL/ACETAMINOPHEN/CAFFEINE/CODEINE CAPS NON_PREFERRED ASCOMP/CODEINE CAPS PREFERRED
Load more

Recommended publications
  • Suitability of Immobilized Systems for Microbiological Degradation of Endocrine Disrupting Compounds
    molecules Review Suitability of Immobilized Systems for Microbiological Degradation of Endocrine Disrupting Compounds Danuta Wojcieszy ´nska , Ariel Marchlewicz and Urszula Guzik * Institute of Biology, Biotechnology and Environmental Protection, Faculty of Natural Science, University of Silesia in Katowice, Jagiello´nska28, 40-032 Katowice, Poland; [email protected] (D.W.); [email protected] (A.M.) * Correspondence: [email protected]; Tel.: +48-3220-095-67 Academic Editors: Urszula Guzik and Danuta Wojcieszy´nska Received: 10 September 2020; Accepted: 25 September 2020; Published: 29 September 2020 Abstract: The rising pollution of the environment with endocrine disrupting compounds has increased interest in searching for new, effective bioremediation methods. Particular attention is paid to the search for microorganisms with high degradation potential and the possibility of their use in the degradation of endocrine disrupting compounds. Increasingly, immobilized microorganisms or enzymes are used in biodegradation systems. This review presents the main sources of endocrine disrupting compounds and identifies the risks associated with their presence in the environment. The main pathways of degradation of these compounds by microorganisms are also presented. The last part is devoted to an overview of the immobilization methods used for the purposes of enabling the use of biocatalysts in environmental bioremediation. Keywords: EDCs; hormones; degradation; immobilization; microorganisms 1. Introduction The development of modern tools for the separation and identification of chemical substances has drawn attention to the so-called micropollution of the environment. Many of these contaminants belong to the emergent pollutants class. According to the Stockholm Convention they are characterized by high persistence, are transported over long distances in the environment through water, accumulate in the tissue of living organisms and can adversely affect them [1].
    [Show full text]
  • SPIRONOLACTONE Spironolactone – Oral (Common Brand Name
    SPIRONOLACTONE Spironolactone – oral (common brand name: Aldactone) Uses: Spironolactone is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat swelling (edema) caused by certain conditions (e.g., congestive heart failure) by removing excess fluid and improving symptoms such as breathing problems. This medication is also used to treat low potassium levels and conditions in which the body is making too much of a natural chemical (aldosterone). Spironolactone is known as a “water pill” (potassium-sparing diuretic). Other uses: This medication has also been used to treat acne in women, female pattern hair loss, and excessive hair growth (hirsutism), especially in women with polycystic ovary disease. Side effects: Drowsiness, lightheadedness, stomach upset, diarrhea, nausea, vomiting, or headache may occur. To minimize lightheadedness, get up slowly when rising from a seated or lying position. If any of these effects persist or worsen, notify your doctor promptly. Tell your doctor immediately if any of these unlikely but serious side effects occur; dizziness, increased thirst, change in the amount of urine, mental/mood chances, unusual fatigue/weakness, muscle spasms, menstrual period changes, sexual function problems. This medication may lead to high levels of potassium, especially in patients with kidney problems. If not treated, very high potassium levels can be fatal. Tell your doctor immediately if you notice any of the following unlikely but serious side effects: slow/irregular heartbeat, muscle weakness. Precautions: Before taking spironolactone, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies.
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Estrogen Actions Throughout the Brain
    Estrogen Actions Throughout the Brain BRUCE MCEWEN Harold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, The Rockefeller University, New York, New York 10021 ABSTRACT Besides affecting the hypothalamus and other brain areas related to reproduction, ovarian steroids have widespread effects throughout the brain, on serotonin pathways, catecholaminergic neurons, and the basal forebrain cholinergic system as well as the hippocampal formation, a brain region involved in spatial and declarative memory. Thus, ovarian steroids have measurable effects on affective state as well as cognition, with implications for dementia. Two actions are discussed in this review; both appear to involve a combination of genomic and nongenomic actions of ovarian hormones. First, regulation of the serotonergic system appears to be linked to the presence of estrogen- and progestin-sensitive neurons in the midbrain raphe as well as possibly nongenomic actions in brain areas to which serotonin neurons project their axons. Second, ovarian hormones regulate synapse turnover in the CA1 region of the hippocampus during the 4- to 5-day estrous cycle of the female rat. Formation of new excitatory synapses is induced by estradiol and involves N-methyl-D-aspartate (NMDA) receptors, whereas downregulation of these synapses involves intracellular progestin receptors. A new, rapid method of radioimmunocytochemistry has made possible the demonstration of synapse formation by labeling and quantifying the specific synaptic and dendritic molecules involved. Although NMDA receptor activation is required for synapse formation, inhibitory interneurons may play a pivotal role as they express nuclear estrogen receptor-alpha (ER␣). It is also likely that estrogens may locally regulate events at the sites of synaptic contact in the excitatory pyramidal neurons where the synapses form.
    [Show full text]
  • Health Effects of Progestins Contained in Cocs, with A
    A PHACTICAL JOURNAL FOR NUHSE PRACTITIONEn5 I i - 1- November 2007 The Official Journal of NPWHj- A 7 .-. Vol. G, No. 11 A Peer-Reviewed Journal &$ Health Effects of Progestins Contained in t COCs, with a -.'P Focus on Norgestimate- -.-I. 21 ? NPWH 2007 ' Annual Conference Abstracts HEALTH EFFECTS OF PROLESTINS CONTAINED IN COCs, WITH A FOGUS ON NORGESTIMATE by Penelope M. Bosarge, MSN, WHNP ased on interviews with more Nurse practitioners (NPs) and their reproductive-aged than 7600 female adolescents and women aged 15 to 44 patients face numerous challenges, particularly when it years, more than 98% who have comes to choosing a method of birth control. If a combined ever had sexual intercourse have used at least one contraceptive oral contraceptive (COC) is judged to be an appropriate meth~d.~The leading method of contraception in the United choice for a given woman, then her NP will need to select a States in 2002 was the Pill, used particular product from among many that are available. by 11.6 million women, and the second leading method was Among the various COC brands on the market, several female sterilization, used by 10.3 million women.2The condom contain norgestimate (NGM), a progestin introduced in was the third-leading method, 1992. Fvteen years of clinical use of NGM-containing used by about 9 million women and their partners. The condom COCs, as well as continued scientz$c investigations of these is the leading method at first intercourse, but the Pill is the products, support their efficacy, safety, and tolerability leading method among women (ie, these products have minimal androgenic and estrogenic younger than 30 yearse2 effects and provide excellent cycle control).
    [Show full text]
  • Medication Use for the Risk Reduction of Primary Breast Cancer in Women: a Systematic Review for the U.S
    Evidence Synthesis Number 180 Medication Use for the Risk Reduction of Primary Breast Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. HHSA-290-2015-00009-I, Task Order No. 7 Prepared by: Pacific Northwest Evidence-Based Practice Center Oregon Health & Science University Mail Code: BICC 3181 SW Sam Jackson Park Road Portland, OR 97239 www.ohsu.edu/epc Investigators: Heidi D. Nelson, MD, MPH Rongwei Fu, PhD Bernadette Zakher, MBBS Marian McDonagh, PharmD Miranda Pappas, MA L.B. Miller, BA Lucy Stillman, BS AHRQ Publication No. 19-05249-EF-1 January 2019 This report is based on research conducted by the Pacific Northwest Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (HHSA-290-2015-00009-I, Task Order No. 7). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment.
    [Show full text]
  • Effect of Different Concentrations of Nandrolone Decanoate on Weights
    Mona Adel Ismail et al /J. Pharm. Sci. & Res. Vol. 10(12), 2018, 3277-3280 Effect of different concentrations of Nandrolone decanoate on weights the testes and Epididymis of male white mice infected with the protoscolices of the Echinococcus granulosus 1Mona Adel Ismail, 1Jasim Hameed Rahmah Al-Khuzaie 1,2University of Kufa / College of Education for Girls/Iraq Abstract This study was conducted in the Animal House of the Department of / Biology / Faculty of Education for girls to detect some of the side effects associated with the use of Nandrolone in the weights of testes and Epididymis of infected with mice protoscolices through the use of (50) male Swiss mice Balb / c age Three months were randomly divided into five equal groups: positive control group, negative control group, and the remaining three groups were injected with concentrations (0.1, 0.2 and 0.3 mg / g) of Nandrolone. The study showed a significant decrease ( P <0.05) in the weights of testes and Epididymis of mice Treatment compared to the positive control group and the negative group. The study also showed that the third concentration (0.3) mg / g of Nandrolone has shown several side effects on certain organs related to the male reproductive system. Keywords: HCD: Hydatids cystic disease, Nandrolone decanoate INTRODUCTION: MATERIALS AND METHODS Hydatids cystic disease, which is widespread in the world, Preparation of the laboratory animals including the Arab world and Iraq, and the incidence of this This study included of 50 adult male of mice - three months old - disease by ingesting the eggs of the Echinococcus granulosus of Balb / c type Mus musculus, and were placed in the Animal with foods that are contaminated with the stool of the final host House of the Department of Biology / Faculty of Education for (Felidae) after hatching eggs onchospher grow and penetration the Girls, which had all laboratory conditions of light (13) (11) hours intestinal wall.
    [Show full text]
  • Molecular and Preclinical Pharmacology of Nonsteroidal Androgen Receptor Ligands
    Molecular and Preclinical Pharmacology of Nonsteroidal Androgen Receptor Ligands Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Amanda Jones, M.S. Graduate Program in Pharmacy The Ohio State University 2010 Dissertation Committee: James T. Dalton, Advisor Thomas D. Schmittgen William L. Hayton Robert W. Brueggemeier Copyright by Amanda Jones 2010 Abstract The androgen receptor (AR) is critical for the growth and development of secondary sexual organs, muscle, bone and other tissues, making it an excellent therapeutic target. Ubiquitous expression of AR impedes the ability of endogenous steroids to function tissue selectively. In addition to the lack of tissue selectivity, clinical use of testosterone is limited due to poor bioavailability and pharmacokinetic problems. Our lab, in the last decade, discovered and developed tissue selective AR modulators (SARMs) that spare androgenic effects in secondary sexual organs, but demonstrate potential to treat muscle wasting diseases. This work reveals the discovery of next generation SARMs to treat prostate cancer and mechanistically characterize a prospective SARM in muscle and central nervous system (CNS). Prostate cancer relies on the AR for its growth, making it the primary therapeutic target in this disease. However, prolonged inhibition, with commercially available AR antagonists, leads to the development of mutations in its ligand binding domain resulting in resistance. Utilizing the crystal structure of AR-wild-type and AR-W741L mutant, we synthesized a series of AR pan- antagonists (that inhibit both wild-type and mutant ARs). Structure activity relationship studies indicate that sulfonyl and amine linkages of the aryl propionamide pharmacophore are important for the antagonist activity.
    [Show full text]
  • Pairwise Comparisons
    National Institute for Health and Care Excellence Final Acne vulgaris: management [E2] Management options for mild to moderate acne – pairwise comparisons NG198 Evidence review underpinning recommendations 1.5.1, 1.5.2 and 1.5.5 to 1.5.14 (excluding 1.5.6 which is underpinned by evidence review L, 1.5.10 and bullet points 2 and 3 of recommendation 1.5.12 which are underpinned by evidence review F1 and 3 research recommendations in the NICE guideline - see evidence review E1 for the committee’s discussion of the evidence) June 2021 Final These evidence reviews were developed by the National Guideline Alliance which is a part of the Royal College of Obstetricians and Gynaecologists FINAL Error! No text of specified style in document. Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.
    [Show full text]
  • The Acceleration of Articular Cartilage Degeneration in Osteoarthritis by Nonsteroidal Anti-Inflammatory Drugs Ross A
    WONDER WHY? THE ACCELERATION OF ARTICULAR CARTILAGE DEGENERATION IN OSTEOARTHRITIS WONDER WHY? The Acceleration of Articular Cartilage Degeneration in Osteoarthritis by Nonsteroidal Anti-inflammatory Drugs Ross A. Hauser, MD A B STRA C T introduction over the past forty years is one of the main causes of the rapid rise in the need for hip and knee Nonsteroidal anti-inflammatory drugs (NSAIDs) are replacements, both now and in the future. among the most commonly used drugs in the world for the treatment of osteoarthritis (OA) symptoms, and are While it is admirable for the various consensus and taken by 20-30% of elderly people in developed countries. rheumatology organizations to educate doctors and Because of the potential for significant side effects of the lay public about the necessity to limit NSAID use in these medications on the liver, stomach, gastrointestinal OA, the author recommends that the following warning tract and heart, including death, treatment guidelines label be on each NSAID bottle: advise against their long term use to treat OA. One of the best documented but lesser known long-term side effects The use of this nonsteroidal anti-inflammatory of NSAIDs is their negative impact on articular cartilage. medication has been shown in scientific studies to accelerate the articular cartilage breakdown In the normal joint, there is a balance between the in osteoarthritis. Use of this product poses a continuous process of cartilage matrix degradation and significant risk in accelerating osteoarthritis joint repair. In OA, there is a disruption of the homeostatic breakdown. Anyone using this product for the pain state and the catabolic (breakdown) processes of of osteoarthritis should be under a doctor’s care and chondrocytes.
    [Show full text]
  • A Randomized, Parallel, Comparative Study of the Efficacy and Safety of Nafarelin Versus Danazol in the Treatment of Endometriosis in Taiwan
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector ORIGINAL ARTICLE A Randomized, Parallel, Comparative Study of the Efficacy and Safety of Nafarelin Versus Danazol in the Treatment of Endometriosis in Taiwan Ming-Huei Cheng1,2, Bill Ken-Jen Yu1–4, Sheng-Ping Chang1,2, Peng-Hui Wang1,2* 1Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, 2National Yang-Ming University School of Medicine, 3Department of Obstetrics and Gynecology, Taipei City Hospital, and 4National Defense Medical Center, Taipei, Taiwan, R.O.C. Background: The purpose of this study was to evaluate the efficacy and safety of nafarelin, a gonadotropin-releasing hormone (GnRH) analogue, versus danazol in the treatment of women with endometriosis in Taiwan. Methods: Fifty-nine women with laparoscopically and pathologically confirmed endometriosis were randomized to receive nafarelin or danazol for 180 days. Efficacy was assessed from mean changes in laparoscopy score (LS) and total symptom severity score (TSSS). Adverse events (AEs) and laboratory parameters, including hematology, hepatic function, blood pressure, and lipid levels, were monitored for safety evaluations. Results: All demographic and baseline factors, except body weight, were comparable between the 2 treatment groups. Both nafarelin and danazol satisfactorily resolved pelvic tenderness, induration, pelvic pain, dysmenorrhea and dyspareunia. No significant differences were noted in efficacy endpoints between nafarelin and danazol regarding LS and TSSS at 90 and 180 days of treatment. No significant difference was observed between the 2 groups regarding the overall incidence of AEs, except for laboratory-related AEs. However, nafarelin tended to have less impact than danazol on aspartate transaminase and alanine transaminase, and nafarelin was better tolerated than danazol regarding changes in lipid profiles.
    [Show full text]
  • Nonsteroidal Anti-Inflammatory Drug Use and Serum Total Estradiol in Postmenopausal Women
    680 Nonsteroidal Anti-inflammatory Drug Use and Serum Total Estradiol in Postmenopausal Women Alana G. Hudson,1 Gretchen L. Gierach,5 Francesmary Modugno,1 Jennifer Simpson,1 John W. Wilson,2 Rhobert W. Evans,1 Victor G. Vogel,3,4 and Joel L. Weissfeld1,4 Departments of 1Epidemiology and 2Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh; 3Department of Medicine, University of Pittsburgh School of Medicine; 4University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania and 5Cancer Prevention Fellowship Program, Office of Preventive Oncology, National Cancer Institute, NIH, Bethesda, Maryland Abstract Laboratory and epidemiologic evidence suggest that were used to evaluate the association between NSAID nonsteroidal anti-inflammatory drug (NSAID) use may use and serum total estradiol. The age-adjusted and be inversely related to the risk of breast cancer; body mass index–adjusted geometric mean serum however, the mechanism by which NSAIDs may protect estradiol concentration among NSAID users (n = 124) against the development of this disease is uncertain. was significantly lower than nonusers of NSAIDs The objective of this observational study was to assess (n = 136; 17.8 versus 21.3 pmol/L; P = 0.03). Further the relationship between current NSAID use and adjustment for additional potential confounding factors endogenous estradiol levels, an established breast did not substantially alter estimates (17.7 versus 21.2 cancer risk factor. To evaluate this aim, we conducted pmol/L; P = 0.03). To our knowledge, this report is the a cross-sectional investigation among 260 postmeno- first to examine the relationship between NSAID use pausal women who were not recently exposed to and serum estradiol in postmenopausal women.
    [Show full text]